3Schatz F, Papp C, Aigner S et al. Biological mechanisms underlying the clinical effects of Ru486: modulation of cultured endometrial stromal cell stromelysin-1 and prolactin expression. J Clin Endocrinol Metab, 1997; 82(1):188.
4Olivares EG,Montes MJ,Oliver C et al. Cultured human decidual stromal cells express B7-1 (CD80)and B7-2, (CD86 and stimulate allogeneic T cells. Biol Reprod, 1997 ; 57 ( 3 ) : 609.
5Buzdar A, Hayes D, El-Khoudary A, et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer [J]. Breast Cancer Res Treat, 2002, 73(2) : 161-175.
6Fuchs WS, Leary WP, van der Meer MJ, et al. Pharmacokinetics and bioavailability of tamoxifen in postmenopausal healthy women[J ]. Arzneimittelforschung, 1996,46 ( 4 ) : 418-422.
7Buzdar AU, Hortobagyi GN, Frye D, etal. Bioequivalence of 20-rag once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens ~or breast cancer[J]. J Clin Oncol, 1994,12(1):50-54.
8Tukker JJ, Blankenstein MA, Nortier JW. Comparison of bioavailability in man of tamoxifen after oral and rectal administration[J]. J Pharm Pharmacol, 1986,38(12):888-892.
